Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2536 to 2550 of 8908 results

  1. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    In development Reference number: GID-TA11130 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]

    In development Reference number: GID-TA11437 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Asunercept for treating glioblastoma [ID1301]

    In development Reference number: GID-TA10227 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Deuruxolitinib for treating severe alopecia areata [ID6597]

    In development Reference number: GID-TA11804 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  6. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  7. Deutetrabenazine for treating tardive dyskinesia [ID6550]

    In development Reference number: GID-TA11718 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]

    In development Reference number: GID-TA11869 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 18 February 2026.

    Technology appraisal guidance
    In consultation

  10. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.

    Technology appraisal guidance
    In consultation

  11. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 20 February 2026.

    Technology appraisal guidance
    In consultation

  12. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

    In development Reference number: GID-TA11405 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death

    In development Reference number: GID-IPG10405 Expected publication date:  19 November 2026

    Interventional procedures guidance
    In development

  14. Ciclosporin (Vevizye) eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    Awaiting development